Korro Bio (KRRO) Expected to Post Earnings on Tuesday

Korro Bio (NASDAQ:KRRO) is anticipated to post its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Korro Bio to announce earnings of ($1.3380) per share and revenue of $0.2140 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 117.86%. On average, analysts expect Korro Bio to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Korro Bio Price Performance

Shares of KRRO stock traded up $0.29 on Tuesday, hitting $11.03. 34,882 shares of the stock traded hands, compared to its average volume of 204,372. The company’s fifty day moving average is $12.29 and its 200 day moving average is $11.99. Korro Bio has a 1-year low of $5.20 and a 1-year high of $55.89. The company has a market capitalization of $159.05 million, a PE ratio of -0.95 and a beta of 3.04.

Analyst Ratings Changes

Several research firms have weighed in on KRRO. Wall Street Zen upgraded shares of Korro Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright dropped their price objective on shares of Korro Bio from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Korro Bio in a research note on Monday, July 6th. Citigroup began coverage on shares of Korro Bio in a research note on Monday, May 18th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, JonesTrading raised Korro Bio from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.71.

Insider Activity at Korro Bio

In other news, CEO Ram Aiyar sold 15,152 shares of the business’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $12.98, for a total value of $196,672.96. Following the sale, the chief executive officer owned 74,848 shares of the company’s stock, valued at approximately $971,527.04. The trade was a 16.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jean Francois Formela sold 9,323 shares of Korro Bio stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $13.96, for a total value of $130,149.08. Following the transaction, the director directly owned 146,305 shares in the company, valued at approximately $2,042,417.80. The trade was a 5.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 306,026 shares of company stock valued at $4,309,637 over the last quarter. Corporate insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Korro Bio

Several hedge funds have recently made changes to their positions in KRRO. Russell Investments Group Ltd. bought a new stake in shares of Korro Bio in the 3rd quarter worth approximately $39,000. Wells Fargo & Company MN boosted its holdings in Korro Bio by 45.5% during the fourth quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock worth $60,000 after buying an additional 2,352 shares in the last quarter. Guggenheim Capital LLC acquired a new position in Korro Bio in the fourth quarter worth approximately $84,000. Jain Global LLC bought a new position in shares of Korro Bio in the fourth quarter valued at $85,000. Finally, Deutsche Bank AG increased its holdings in shares of Korro Bio by 241.9% in the fourth quarter. Deutsche Bank AG now owns 12,758 shares of the company’s stock valued at $102,000 after buying an additional 9,027 shares in the last quarter. Institutional investors and hedge funds own 13.18% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.